Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Interferon gamma release assay

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Interferon gamma release assay. Displaying page 1 of 1.
    EudraCT Number: 2021-000349-42 Sponsor Protocol Number: DurIRVac-1 Start Date*: 2021-03-26
    Sponsor Name:Sahlgrenska Academy, University of Gothenburg
    Full Title: Evaluation of the Durability of Immune Responses to SARS-CoV-2 Using Novel Rapid Spike Interferon-Gamma Release and Activation-Induced Marker Assays and Anti-Spike IgG Following COVID-19 Vaccination
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000750-21 Sponsor Protocol Number: 12/0426 Start Date*: 2013-12-18
    Sponsor Name:University College London
    Full Title: The HALT-LTBI study: Phase IV, multi-site, unblinded, randomised trial of prophylactic daily rifampicin/isoniazid vs. weekly rifapentine/isoniazid for latent tuberculosis infection (LTBI)
    Medical condition: Latent tuberculosis infection
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004786-80 Sponsor Protocol Number: ANAKIN Start Date*: 2019-02-20
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty
    Full Title: A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis.
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10028141 Mucoviscidosis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001316-26 Sponsor Protocol Number: APHP200007 Start Date*: 2022-09-12
    Sponsor Name:Assistance Publique Hôpitaux de Paris / DRCI
    Full Title: Multicenter, randomized, prospective trial comparing the Efficacy and Safety of Adalimumab to that of Tocilizumab in severe uveitis of Behçet’s disease UVB Study
    Medical condition: severe uveitis of Behçet’s disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10071139 Behcet's uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003753-13 Sponsor Protocol Number: P160909 Start Date*: 2019-03-19
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Full Title: Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis
    Medical condition: Patients with refractory or relapsing Takayasu Arteritis desease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003653-16 Sponsor Protocol Number: S62092 Start Date*: 2019-03-21
    Sponsor Name:UZ Leuven
    Full Title: Abatacept in patients with Birdshot HLA A29 uveitis: A Phase II Prospective 0pen Label Interventional Proof-of-Concept Study
    Medical condition: Birdshot Uveitis HLA A29 retinochoroiditis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10072959 Birdshot chorioretinopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001314-42 Sponsor Protocol Number: IM103116 Start Date*: 2013-09-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (belatacept)-based Immunosuppression
    Medical condition: Maintenance of renal transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003255-54 Sponsor Protocol Number: RGB-03-104 Start Date*: 2015-01-21
    Sponsor Name:Gedeon Richter Plc
    Full Title: A Double-blind, Randomised, Comparative Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Evaluation of RGB-03 and MabThera® Combined with Methotrexate in Rheumatoid Arthritis Patients
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-004444-29 Sponsor Protocol Number: RID-TB:Treat Start Date*: 2020-11-25
    Sponsor Name:University College London
    Full Title: An open-label, multi-centre, randomised controlled trial evaluating the effects of short-course rifapentine-based regimens and additional adherence support on LTBI treatment adherence and completio...
    Medical condition: Latent Tuberculosis infection (LTBI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002264-41 Sponsor Protocol Number: P160932J Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude randomisée multicentrique évaluant l’efficacité et la tolérance de l’infliximab comparativement au Cyclophosphamide dans les formes sévères de maladie de Behçet " Multicenter, randomized, pro...
    Medical condition: Induction Therapy with Anti-TNF vs Cyclophosphamide in severe Behçet disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000017240 10004212 Behcet's disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004497-10 Sponsor Protocol Number: CT-P13-3.4 Start Date*: 2014-07-16
    Sponsor Name:Celltrion, Inc.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess the Safety of CT-P13 Compared to Remicade in Patients With Active Crohn’s Disease
    Medical condition: Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10058815 Crohn's disease acute episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) GB (Completed) IT (Completed) ES (Completed) RO (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004468-31 Sponsor Protocol Number: CT-P13-3.2 Start Date*: 2012-01-06
    Sponsor Name:CELLTRION, Inc
    Full Title: An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patients With Rheumatoid Arthritis Who Were Treated With ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) ES (Completed) LV (Completed) SK (Completed) LT (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002713-19 Sponsor Protocol Number: VIB4920.P2.S2 Start Date*: 2020-01-15
    Sponsor Name:Viela Bio, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in subjects with Sjögren’s Syndrome (SS)
    Medical condition: Sjögren's syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10059142 Sjoegren's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000372-95 Sponsor Protocol Number: ALX0061-C204 Start Date*: 2015-08-20
    Sponsor Name:Ablynx N.V.
    Full Title: A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate ...
    Medical condition: Moderate to Severe Active Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000017968 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) PT (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 14:45:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA